Phase 4 N=9 C. Difficile and Ursodiol
Diarrhea
Primary: Percent of Patients With Return Toward a Normal Fecal Bile Acid Pattern — 100 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=33 Impact of Oral Antibiotic Treatment on C. Difficile
C. Difficile · Diarrhea · Enterocolitis
Primary: Change in Total Median Total Colony Forming Units (CFU) of C. Difficile Identified in the Hospital Room Environment for Each Antibiotic Treatment Group. — 56; 33; 149; 7…
N/A N=3,153 COMBACTE-CDI Understanding the Burden of C. Difficile Infection
Clostridium Difficile Infection
Primary: The Number of Cases of CDI — 103; 0 Participants
Phase 2 N=9 Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
Clostridium Difficile Infection · Hematologic Diseases · Bone Marrow Transplant
Primary: Changes in Clostridium Difficile Bacterial Loads in the Stool — 62102500.00; 40000000.00; 7752750.00; 185000.00 CFUs
Phase 3 N=17,535 Clostridium Difficile Vaccine Efficacy Trial
Clostridium Difficile Infection
Primary: Number of First Primary Episodes of Clostridium Difficile Infection (CDI) (Definition 1) Follow-up After Dose 3 — 17; 25 Episodes
N/A N=403 Antimicrobial Stewardship Program for Clostridium Difficile Infection.
Clostridium Difficile · Enterocolitis, Pseudomembranous
Primary: Number of Participants With Clostridium Difficile Infection Recurrence. — 34; 21 Participants — p=0.56
Phase 2 N=133 Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
Enterocolitis Clostridium Difficile Recurrent
Primary: Treatment Success of Group A (2 Doses of RBX2660) vs Group B (2 Doses of Placebo) (ITT) — 25; 19; 20; 25 Participants
Phase 2 N=413 A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
Clostridium Difficile · Clostridium Infections
Primary: Percentage of Patients With Clostridium Difficile Infection at 4- Weeks of Follow-up. — 2; 7 Participants — p=0.045
Phase 2 N=200 Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
Clostridium Infections
Primary: Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) — 7; 25 Participants
Phase 2 N=34 Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea
Recurrent Clostridium Difficile Infection
Primary: Incidence of Serious Adverse Events Through 56 Days After the Last Treatment With RBX2660 — 10 number of reported SAEs through 56 days
Phase 2 N=13 Early FMT for C.Difficile
Clostridium Difficile
Primary: Clinical Remission Rates — 3; 2 Participants
Phase 2 N=210 Study of CB-183,315 in Participants With Clostridium Difficile Infection
Clostridium Difficile Infection · Diarrhea
Primary: Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment — 61; 58; 59 participants
Phase 4 N=674 Screening to Prophylax Against Clostridium Difficile Infection -
Clostridium Difficile Infection
Primary: The Incidence of CDI in Inpatients Receiving Vancomycin Prophylaxis vs. Placebo Who Are on High-risk Antibiotics and Are Colonized With Toxigenic C. Difficile. — 0; 0…
Phase 2 N=10 ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection
Clostridium Difficile Infection
Primary: Segment 2A: Clinical Cure (CC) of Clostridioides Difficile Infection (CDI) Per Protocol (PP)/Modified Intent-to-Treat (mITT) Population — 10; 0 Participants
Phase 1 N=50 Safety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult Volunteers
Clostridium Infections
Primary: Number of Participants Reporting Solicited Injection Site Erythema and Tenderness Post-vaccination With Either One of Three Formulations of Clostridium Difficile…
Phase 4 N=34 Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin
Clostridium Difficile Infection
Primary: C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool — 11; 6 Participants
Phase 4 N=15 TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment
Clostridium Difficile Infection · Diarrhea
Primary: Number of Participants With Detectable C. Difficile — 5; 4 Participants
Phase 2 N=206 Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
Clostridium Difficile Infection Recurrence
Primary: Number of Participants With Absence of Recurrence Through Week 8 Based on Adjudication — 76; 59 Participants — p=0.0488
Phase 3 N=608 A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)
Clostridium Difficile Infection
Primary: Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT) — 83.4; 82.1 Adjusted percentage of participants
Phase 2 N=68 Fecal Microbiota Transplantation to Treat Recurrent C. Difficile Associated Diarrhea Via Retention Enema or Oral Route
C. Difficile
Primary: Safety as Assessed by Number of Participants With Any Adverse Events (AE)s — 4; 4 Participants — p=0.8958
Phase 2 N=42 A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
Clostridium Difficile Associated Disease
Primary: Percentage of Participants Reporting Prespecified Local Reactions Within 7 Days After Dose 1 (50- to 64-Year Age Cohort) — 16.7; 16.7; 50.0; 16.7 Percentage of…
N/A N=780 Effect of Expanding (Gloving) Barrier Precautions for Reducing Clostridium Difficile Acquisition (and Infection) in VA
Clostridium Difficile
Primary: C. Difficile Acquisition Rates — 13.2; 10.4 C. diff acquisition per patient days — p=0.611
Phase 1 N=140 Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years
Clostridium Infections
Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms, After Each Vaccine Dose — 0; 0; 0; 8 Participants
Phase 2 N=78 Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea
Recurrent C. Difficile Associated Diarrhea
Primary: Safety of Fresh, Frozen or Lyophilized Intestinal Bacteria From Healthy Donors Given by Colonoscopy for Therapy in Subjects With Recurrent C. Difficile Associated…
Phase 3 N=606 Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)
Clostridium Difficile Infection
Primary: Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT) — 79.0; 83.6 Percentage of participants
Phase 3 N=1,994 Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study
Clostridium Difficile Associated Disease
Primary: Adjusted Geometric Mean Concentration (GMC) of Clostridium Difficile Toxin A and Toxin B Specific Neutralizing Antibodies at Month 7 for Evaluable Immunogenicity…
N/A N=600 Prospective Observational Study of Clostridium Difficile Infection in Asian Pacific Countries
Clostridium Difficile Infection
Primary: Patient Demographics — 54; 46; 63; 29 participants
Phase 1 N=48 Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers
Clostridium Infections
Primary: Number of Participants Reporting Treatment-Emergent Adverse Events Post-vaccination With Either One of Three Formulations of the Clostridium Difficile Vaccine or a…
Phase 3 N=27 Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
Clostridium Enterocolitis · Pseudomembranous Colitis
Primary: Nitazoxanide — 27 participants
Phase 4 N=51 Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics
Clostridium Difficile Infection · Prophylaxis · Vancomycin
Primary: Clostridium Difficile Infection Occurrence — 2; 0 Participants